Insmed’s PhII smokes and sputters, but researchers herald enough surprisingly positive data to roar on Wall Street
There was plenty not to like in Insmed’s Phase II readout of an anti-inflammatory drug dubbed INS1007.
The dose response didn’t pan out and in fact, the high dose missed on a key endpoint that could be the pivotal goal needed for an approval. But with several analysts expecting the whole thing to be a bust, investors cheered on evidence of positive efficacy in treating non-cystic fibrosis bronchiectasis and ran up the stock price $INSM by 40%.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,600+ biopharma pros reading Endpoints daily — and it's free.